Article
A method for screening and validation of resistant mutations against kinase inhibitors.
Journal of visualized experiments : JoVE - 7 Dec 2014
Kesarwani Meenu, Huber Erika, Kincaid Zachary, Azam Mohammad
Abstract excerpt
The discovery of BCR/ABL as a driver oncogene in chronic myeloid leukemia (CML) resulted in the development of Imatinib, which, in fact, demonstrated the potential of targeting the kinase in cancers by effectively treating the CML patients. This observation revolutionized drug development to target the oncogenic kinases implicated in various other malignancies, such as, EGFR, B-RAF, KIT and PDGFRs. However, one...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.